Biotest
Marlene Fehling has extensive work experience in the pharmaceutical industry. Marlene started their career at Novartis in 1990 as a Clinical Programmer, where they focused on SAS Programming for clinical study reports in the areas of oncology and malaria. Marlene collaborated with clinical study teams to design descriptive summaries and data listings for demographic and safety data. After seven years at Novartis, Marlene joined Biotest AG in 1997 as the Head of Corporate Drug Safety Systems. The information regarding their role at Biotest AG does not provide specific start and end dates.
Marlene Fehling obtained a Master's degree in Agriculture from the Technical University of Munich, completing their studies from 1984 to 1990. Marlene also holds additional certifications in Person centered counseling (AKT) and is a Certified Project Management Associate IPMA Level D. Marlene has expertise in auditing and computer validation within the pharmaceutical IT field.
This person is not in any teams
Biotest
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.